Results from these trials will form the basis of any future regulatory submission
The evidence is there
Previous insulin use and previous glucocorticoid use were identified through redeemed prescriptions (binary variables)
Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks
Now it takes everything you have just to get through the week and your doctor says your labs are normal
CareClinics GLP-1 Shot Tracker helps you: Set personalized reminders that fit your schedule, whether your medication is weekly (like Ozempic or Wegovy) or on another schedule Track your injection sites with our body map feature, helping you rotate properly between your abdomen, thigh, and arm locations to prevent tissue damage and ensure optimal absorption Document your dosage progression as your provider adjusts your treatment plan, from starter doses through maintenance therapy Set refill reminders so you never run out of medication, especially given the current supply challenges with many GLP-1 medications I was constantly forgetting which day I took my Ozempic and where I last injected
